Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
9.61
+0.34 (3.67%)
Aug 27, 2025, 4:00 PM - Market closed
Evolent Health Employees
Evolent Health had 4,500 employees as of December 31, 2024. The number of employees decreased by 200 or -4.26% compared to the previous year.
Employees
4,500
Change (1Y)
-200
Growth (1Y)
-4.26%
Revenue / Employee
$487,982
Profits / Employee
-$41,152
Market Cap
1.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,500 | -200 | -4.26% |
Dec 31, 2023 | 4,700 | -400 | -7.84% |
Dec 31, 2022 | 5,100 | 1,600 | 45.71% |
Dec 31, 2021 | 3,500 | 600 | 20.69% |
Dec 31, 2020 | 2,900 | -500 | -14.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EVH News
- 6 days ago - Evolent's Soft Q2 Results: Why I'm Holding Anyway - Seeking Alpha
- 8 days ago - Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire
- 9 days ago - Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire
- 18 days ago - Evolent Health, Inc. (EVH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Evolent Announces Second Quarter 2025 Results - PRNewsWire
- 6 weeks ago - Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - PRNewsWire
- 7 weeks ago - Evolent announces key appointments to leadership team - PRNewsWire
- 2 months ago - Evolent reiterates Q2 and full year guidance for Adjusted EBITDA - PRNewsWire